A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown.
Mycobacterium tuberculosis (TB) is the sixth-largest cause of death overall in low-income countries [1] . Ambitious global targets for reducing TB incidence and mortality are unlikely to be achieved without additional interventions to address the tremendous burden of latent TB infection (LTBI) [2] . Treating LTBI is particularly important for people living with human immunodeficiency virus (PLWH), as untreated human immunodeficiency virus (HIV) increases the risk of TB reactivation ≥20-fold [3] . Since the early 1990s, isoniazid preventive therapy (IPT)-300 mg of daily isoniazid for 6-12 months-has been the standard regimen for LTBI treatment [4] . IPT has demonstrated substantial individual-level impact in major trials, but its impact on the global TB epidemic has been limited, in part due to the challenges of implementing a daily regimen lasting 6 months or more [5, 6] . In 2011, a novel regimen consisting of 12 doses of weekly, directly observed therapy with 900 mg isoniazid and 900 mg rifapentine (3HP) was shown to be at least as effective as 9 months of daily isoniazid [7] ; subsequent studies have confirmed 3HP's efficacy and higher completion rates [8, 9] . The World Health Organization (WHO) now strongly recommends 3HP as an alternative to IPT in healthy adults and PLWH, though concerns exist regarding drug-drug interactions with newer antiretroviral therapy (ART) regimens [10] . As rifapentine is substantially more expensive than isoniazid, economic concerns are critical to address if 3HP is to be scaled up more broadly. We therefore sought to describe the conditions under which 3HP is likely to be cost-effective relative to IPT for prevention of TB among PLWH on ART.
METHODS

Population and Model Design
We developed a Markov state transition model in a hypothetical cohort of 1000 PLWH on ART to compare incremental costs, effectiveness, and cost-effectiveness of 2 preventive TB therapies-12 weeks of once-weekly therapy with 3HP and self-administered daily isoniazid with monthly follow-up (IPT, taken for 9 months in the reference scenario, for comparability with trial results). Model parameters and structure were chosen to represent a Ugandan HIV clinic (as a low-income setting where A, Simplified version of the deterministic portion of the model, including the time during which individuals are on preventive therapy. Those who do not die during this period progress to the Markov portion of the model (B), with the reference-level efficacy of preventive therapy (ie, reduction in risk of reactivation in future years) listed. Those without latent tuberculosis enter the Markov portion of the model with no risk of reactivation. In this section, we evaluate individuals during timesteps of 1 year over a 20-year time horizon with a defined probability of disengaging from antiretroviral therapy during the first 3 years only. Probabilities for each subbranch and disability weights can be found in Table 1 . In this diagram, circles represent Markov nodes (cycling to a Markov state in the subsequent time step), whereas squares represent death. Abbreviations: 3HP, 3 months (12 doses) of weekly isoniazid and rifapentine; 9H, 9 months isoniazid; ART, antiretroviral therapy; HIV, human immunodeficiency virus; LTBI, latent tuberculosis; TB, tuberculosis.
3HP might be adopted), but we conducted sensitivity analyses to also represent other settings. Our population consisted of all eligible individuals initiating TB preventive therapy, assuming the same screening (and loss to follow-up) processes would occur prior to initiating 3HP or standard IPT. Thus, we do not assume screening for LTBI prior to treatment, but we include a scenario with a higher prevalence of LTBI, commensurate with the positive predictive value of LTBI assays to detect TB infection, to account for this possibility ( Figure 1A) .
In the reference case, we assumed that TB preventive therapy would not change the cost of ART (eg, due to required dose adjustment). Rates of adverse events-defined as any medical event permanently interrupting therapy-were assumed to be equivalent between 3HP and IPT, based conservatively on evidence from 1 clinical trial in HIV-infected persons [11] , though other trials [8, 12] suggest lower toxicity with 3HP. During the first 3 years following TB preventive therapy, we assumed an annual rate of (permanent) disengagement from ART care [13] that was independent of IPT/3HP completion status. For simplicity (lacking representative data on long-term rates of engagement and disengagement), we assumed that individuals remained either engaged or disengaged in ART care after 3 years.
Markov states included TB states (uninfected, latent, active) and HIV states (ART engaged/disengaged), each with corresponding disability weights ( Figure 1B) . Disability weights and model costs are given in Table 1 ; in the absence of accepted values, we assumed a constant disability associated with active TB, rrespective of ART status. Model costs included the unit price of drugs used for preventive therapy, the annual cost of delivering ART, costs of treating active TB, and the cost of outpatient visits; we assumed equivalent per-visit costs for 3HP (weekly) and IPT (monthly). Laboratory monitoring for people on treatment for LTBI is not routinely performed in Uganda and was thus not included. Similarly, we did not explicitly incorporate additional costs of treating HIV-associated opportunistic infections, including any episodes of TB due to reinfection after receipt of LTBI treatment. The unit price of rifapentine (150 mg) was taken from current reports, with additional sensitivity analyses considering future price reductions [14] . Costs were reported in US dollars and adjusted to the year 2017 using the US Consumer Price Index [15] . We used a 20-year time horizon for our analysis, with future costs and effectiveness discounted at 3% per year.
LTBI Prevalence, Rates of Reactivation, and Mortality Rates
LTBI prevalence was calculated from the estimated rate of TB infection from nearby Tanzania, assuming exponential decay over a mean of 25 years [16] . After prescreening, individuals were assumed to not develop active TB during preventive therapy. The baseline efficacy of both 3HP and IPT in preventing reactivation came from a meta-analysis of clinical trials [9] . For purposes of interpretation, we defined "completion" in binary fashion: "noncompleters, " or those who initiated preventive therapy but were lost to follow-up (or experienced an adverse event), were assumed to incur 1 month of costs but achieve no In the base case, given that data on the proportion completing 3HP in the field are limited, we assumed that 3HP would reduce loss to follow-up by 50% relative to IPT. c Thirty-six 300-mg tablets of isoniazid (at base level of $0.02 per tablet) and seventy-two 150-mg tablets of rifapentine. Only the isolated price of rifapentine was considered in analyses. protective effect [30] . "Completers" were defined as those who received full protection (typically measured in trials as receipt of at least 10 doses) and incurred full treatment costs. For these individuals, we assumed a constant, lifelong reduction in the risk of active TB from reactivation [22] , with no protection against reinfection. Individuals who completed partial courses and received partial protection can therefore be conceptualized as contributing to a weighted average of completers and noncompleters. Those who disengaged from HIV care also had increased risks of developing (and dying from) active TB [18, 31] . We assumed that all deaths from active TB occurred within a year [32, 33] . Mortality estimates for individuals off ART was gathered from an open cohort of 19 983 adults (aged 15-59 years) in Rakai, Uganda [18] . We estimated mortality on ART from a prospective cohort study of >22 000 Ugandan adults (median age of 37 years) initiating ART [17] and assumed that people with active TB experienced HIV-specific plus TB-specific mortality. We assume that these mortality rates are inclusive of any mortality resulting from TB reinfection.
Sensitivity Analyses
We conducted 1-way sensitivity analyses on model parameters to determine their effects on the incremental cost-effectiveness of 3HP. Additional 3-way sensitivity analyses were performed on key parameters: LTBI prevalence, and relative efficacy and completion rate of 3HP. We considered cost-effectiveness thresholds between $1000 and $9000 per disability-adjusted life-year (DALY) averted. We also performed a sensitivity analysis in which we considered costs for 6, rather than 9, months of IPT. Analyses were performed in TreeAge Pro 2017 (TreeAge, Williamstown, Massachusetts) and Microsoft Excel 2016 (Microsoft, Redmond, Washington) software.
RESULTS
Cost-effectiveness and Clinical Outcomes
In the reference scenario and compared to IPT, we estimated that, per 1000 PLWH in a Ugandan HIV clinic, 3HP would avert 9 cases of active TB (of 37 that would occur with IPT), 1 death (of 466), and 5.8 DALYs over a 20-year time horizon.
The (Table 2) . Use of a 40-year horizon moderately decreased our results (ICER $5647 per DALY averted).
Parameters Influencing the Incremental Cost-effectiveness of 3HP
Cost-effectiveness of 3HP was most strongly influenced by completion rates (Figure 2) . If 3HP and IPT achieved similar completion, the estimated incremental cost-effectiveness of 3HP was $62 182 per DALY averted, but this ratio could be reduced to $6986 per DALY averted if 3HP could be delivered in the field with the same completion rates as in clinical trials (89% vs 47% for IPT). Variations in both the prevalence of LTBI and the price of 3HP regimen also greatly affected the cost-effectiveness of 3HP. When the prevalence of LTBI in our cohort increased from 11% to 44% [30], the incremental cost-effectiveness of 3HP relative to IPT decreased from $22 565 to $6070 per DALY averted. Similarly, reducing the price of 3HP from $72 to $15 per patient course improved the incremental cost-effectiveness of 3HP from $9402 to $535 per DALY averted.
Conditions for 3HP Cost-effectiveness
We then varied 4 primary determinants of cost-effectiveness (incremental efficacy, incremental adherence, LTBI prevalence, and the price of 3HP) to describe the settings in which 3HP would be cost-effective at different thresholds ( Figure 3 ). Assuming equal efficacy ( Figure 3A-C) , 3HP could achieve cost-effectiveness at a $5000-per-DALY-averted threshold relative to IPT if, for example, the price of 3HP were $35, prevalence of LTBI among treatment recipients were 20%, and 87% of 3HP recipients could complete a sufficient amount of doses to receive full protective effect. In the same setting, at a $9000-per-DALY-averted threshold, 3HP could achieve cost-effectiveness at a 3HP price of $57 or completion of 67%. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be reduced to $20 per course and exceptionally high completion (85%) can be achieved or if the price can be reduced to as little as $8 with 67% completion. Increases in the efficacy of 3HP ( Figure 3D-F) , LTBI prevalence among treatment recipients ( Figure 3C and 3F vs Figure 3A and 3D), completion of 3HP relative to IPT, and willingness to pay all increased the ability of 3HP to achieve cost-effectiveness-as did reductions in 3HP price. Results were similar, regardless of whether we considered costs of 6 vs 9 months of IPT as the comparator (data not shown).
DISCUSSION
This analysis illustrates the conditions under which 3HP is likely to be cost-effective relative to standard IPT. As shown in Figure 3 , 3HP is likely to be considered cost-effective in settings with a higher willingness-to-pay threshold (eg, upper-middle-income countries) under our reference conditions, but for 3HP to be cost-effective in lower middle-income settings such as Uganda (per-capita gross national income: $1820) [34] , the price of 3HP must be reduced substantially (to about $20 per course), and unless the price can be reduced even further (to $8 or less, see WTP = $1000 line in Figure 3D ), completion rates similar to those seen in clinical trials must be achieved. These findings argue strongly for reducing the price of rifapentine and exploring interventions such as digital health technology (including electronic medication reminders) [35] to enhance 3HP completion in high-burden settings.
A common metric for determining cost-effectiveness is per-capita gross national income (GNI) or gross domestic product per DALY averted as "highly cost-effective" [34] . According to this metric, assuming equal efficacy and our reference-level completion levels, low-income countries (per-capita GNI <$1005) [36] would find 3HP cost-effective only if the current price of 3HP can be reduced to $10-$20, and even then, if 3HP could be delivered either to people with high LTBI prevalence or with levels of completion seen in clinical trial settings (89%) [11] . Ways to target 3HP to populations with high LTBI prevalence include contact investigation and testing for LTBI prior to initiation of treatment; although these interventions will not substantially affect the incremental cost of 3HP relative to standard IPT (if carried out similarly in both scenarios), they will increase program costs relative to no preventive therapy. Lowermiddle-income countries (per-capita GNI of $1006-$3955) may find 3HP to be cost-effective at more reasonable levels of completion (~70%) if LTBI prevalence in the target population is 50% and the per-course cost of 3HP can be reduced to $35 Abbreviations: 3HP, 3 months (12 doses) of weekly isoniazid and rifapentine; ART, antiretroviral therapy; DALY, disability-adjusted life-year; IPT, isoniazid preventive therapy (9 months of daily isoniazid); TB, tuberculosis; USD, US dollars. a Values listed for IPT and 3HP alone are expressed as incremental to no preventive therapy.
( Figure 3B , WTP = $3000 line). Upper-middle-income countries (per-capita GNI of $3956-$12 235) would find 3HP to be cost-effective in most cases, even at existing prices for 3HP. These perspectives on cost-effectiveness do not speak to affordability but can be used to aid decisions about when and where to implement 3HP based on individual programs' financial capacities and epidemiologic context. We assumed, in our reference scenario, similar efficacy among patients completing 3HP (63%) and IPT (58%) [9] . If the true efficacy of 3HP is substantially higher-as in a second trial demonstrating a 71% lower risk of reactivation in those receiving 3HP vs IPT [11] -our cost-effectiveness estimates for 3HP may be conservative. Postimplementation evaluations of TB incidence after taking 3HP and IPT in larger populations of PLWH could therefore help refine the cost-effectiveness estimates presented here. Additional research to evaluate the levels of completion that can be achieved with 3HP after actual implementation in different settings is likewise essential.
Other economic evaluations comparing the 2 treatments in lower-burden settings are broadly consistent with our results, suggesting cost-effectiveness of 3HP in settings with higher willingness-to-pay thresholds [37] [38] [39] . Our analysis extends these findings to the high-burden settings where 3HP is likely to have the greatest epidemiological impact and illustrates the conditions under which 3HP is likely to meet standard thresholds for cost-effectiveness in those contexts.
This study has important limitations. First, parameter values were gathered from published literature and not empirically measured; these values are also specific to those of an HIV clinic in a low-income sub-Saharan country. Thus, results may not fully generalize to other settings. Second, we assumed that the efficacy of preventive therapy against TB reactivation remains consistent throughout an individual's life, though we do not assume any protection against reinfection. Importantly, of greatest relevance to this analysis is the incremental effectiveness of 3HP relative to IPT; further data on the long-term effectiveness of 3HP will improve estimates of cost-effectiveness. Third, we did not consider secondary transmission of infection in the population and thus may have underestimated the cost-effectiveness of TB preventive therapy at the population level-though again this concern is somewhat mitigated by our focus on incremental effectiveness of 3HP relative to IPT (rather than of preventive therapy vs no treatment). Fourth, the implementation of 3HP at a national level is a complex task, and we did not consider other costs and effects of the implementation process itself, including any differential in patients' willingness to accept 3HP relative to standard IPT. Fifth, our study is performed from the health system perspective and does not incorporate other societal costs (eg, costs to patients). The cost-effectiveness of self-administered 3HP might be even more favorable from a societal perspective, as fewer clinic visits might translate into lower costs for patients, though these costs are relatively small ($1.14-$8.00 in one analysis [40] ) and were not major contributors to cost-effectiveness estimates. Finally, our modeling approach is highly simplified; for example, we include only 2 HIV states (on vs off ART). This approach helps to highlight the most important considerations related to cost-effectiveness of 3HP but may not precisely estimate cost-effectiveness as implemented in specific, real-world settings.
In summary, this model of TB preventive therapy for PLWH on ART in high-burden settings predicts that 3HP can be cost-effective relative to IPT, but only if willingness to pay is high, 3HP facilitates substantial increases in completion, or the price of 3HP can be substantially reduced. The cost-effectiveness of 3HP is also greatest in areas where preventive therapy is delivered to people with a high prevalence of LTBI. As preventive therapy for TB becomes an increasingly important tool for advancing the goal of TB elimination in high-burden countries, these results can help decision makers implement this critical intervention in a cost-effective fashion. 
